|
| |
| |
Since joining Pfizer in 1987, Shama Kajiji has held leadership positions on many oncology projects including Multidrug Resistance, Ras signaling, Apoptosis, and inhibition of c-Met tyrosine kinase. Shama’s drug discovery and development experience encompasses small molecules and human antibodies, some of which successfully progressed to Phase 3 studies. She is listed as a co-inventor on 10 patents and has published extensively in peer-reviewed journals. In order to better integrate the business and scientific objectives of the company, she completed an Executive MBA from the University of Rhode Island in 1998. This business training plus her Discovery - Development experience with in-house candidates and external licensing opportunities prepared her for taking on the newly created role of leading the Attrition Analysis Office at Pfizer.
She holds an undergraduate degree from the University of Bombay, a Masters in Immunology, and a Doctorate in Biochemical Pharmacology and Experimental Pathology from Brown University. Her focus was Cancer Research with an emphasis on human pancreatic cancer. She continued this work as a Post-Doctoral Fellow at Scripps Research Clinic and Foundation in La Jolla, CA. under a grant from the NIH and Lilly, to identify novel antigens for inhibiting the invasion and metastasis of pancreatic cancer. This resulted in her discovery of the 4 integrin.
In its current role, the Attrition Analysis Office provides decision support to Pfizer’s R&D leadership for designing strategic and operational imperatives to decrease candidate attrition. These analytics drive risk management strategies for portfolio prioritization and the identification of new initiatives/technologies to continually improve drug discovery-development paradigm(s) for realizing our productivity goals. |
| |
| Back to Editorial |
| |
| |
|
|
|
|
| |
